Literature DB >> 35146358

Mucormycosis in COVID-19: A systematic review of literature.

Shivaraj Nagalli1, Nidhi Shankar Kikkeri2.   

Abstract

Coronavirus disease 2019 (COVID-19) is an acute viral illness caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Opportunistic infections such as mucormycosis have been reported among COVID-19 patients particularly in South Asian countries during the second wave of this pandemic. It is necessary to re-evaluate any changes in traditional risk factors associated with mucormycosis such as diabetes mellitus, organ transplant, etc in the precedent of ongoing COVID-19 pandemic. We conducted a systematic review using electronic databases. A total of 115 COVID-19 patients who were diagnosed with mucormycosis were included in this study. Diabetes mellitus was the most common co-morbidity with 77.1%, followed by hypertension (29.5%) and renal disease (14.3%). 55.2% of the patients had received dexamethasone for COVID-19 infection. Ten patients (11.5%) had received tocilizumab. Sinuses were the most common site of mucormycosis among COVID-19 patients at 79.4% with maxillary sinus (47.4%) being most commonly infected. Orbits were the second most prevalent site at 56.7% and lungs were infected with mucor at 11.3%. The mean duration between the diagnosis of COVID-19 infection and mucormycosis was 16.15 days (range 2-90 days). Cavernous sinus was either infiltrated or encased in 14 patients (14.4%). Cerebral involvement was seen in terms of abscess, infarcts, or edema in 12 patients (12.4%). Only 76 patients had data on the outcomes, out of which 37 (48.7%) patients had died. Diabetes mellitus is still the most common co-morbidity similar to non-COVID-19 patients. More than 90% of the patients with COVID-19 infection had received steroids. Complications such as cavernous sinus thrombosis, cerebral infarcts, abscesses were common. Indiscriminate use of steroids in patients needs to be avoided and focus needs to be put on tight blood sugar control in diabetic patients. Studies are needed to confirm the role of the SARS-CoV-2 virus in causing immune dysfunction and mucormycosis.
Copyright © 2016 - 2021 InfezMed.

Entities:  

Keywords:  COVID-19; Mucormycosis; diabetes mellitus; sinus; steroids

Year:  2021        PMID: 35146358      PMCID: PMC8805463          DOI: 10.53854/liim-2904-2

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  42 in total

1.  Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India.

Authors:  Hardeva Ram Nehara; Inder Puri; Vipin Singhal; Sunil Ih; Bhagirath Ram Bishnoi; Pramendra Sirohi
Journal:  Indian J Med Microbiol       Date:  2021-05-26       Impact factor: 0.985

2.  Maxillofacial Infections in Covid-19 Era-Actuality or the Unforeseen: 2 Case Reports.

Authors:  D Sai Krishna; Harsha Raj; Pranav Kurup; Mehak Juneja
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-05-17

3.  Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19).

Authors:  Mahboobeh Karimi-Galougahi; Shima Arastou; Sara Haseli
Journal:  Int Forum Allergy Rhinol       Date:  2021-03-13       Impact factor: 3.858

4.  Pulmonary aspergillosis and mucormycosis in a patient with COVID-19.

Authors:  Andre K Johnson; Zeron Ghazarian; Kristina D Cendrowski; Jon G Persichino
Journal:  Med Mycol Case Rep       Date:  2021-04-07

5.  Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy.

Authors:  Christoph Zurl; Martin Hoenigl; Eduard Schulz; Stefan Hatzl; Gregor Gorkiewicz; Robert Krause; Philipp Eller; Juergen Prattes
Journal:  J Fungi (Basel)       Date:  2021-01-27

6.  Mucormycosis associated with COVID-19 in two kidney transplant patients.

Authors:  Carolt Arana; Rafael E Cuevas Ramírez; Marc Xipell; Joaquim Casals; Asunción Moreno; Sabina Herrera; Marta Bodro; Frederic Cofan; Fritz Diekmann; Núria Esforzado
Journal:  Transpl Infect Dis       Date:  2021-06-13

7.  Mucormycosis of Paranasal Sinuses of Odontogenic Origin Post COVID19 Infection: A Case Series.

Authors:  Poonam Kumar Saidha; Sahil Kapoor; Pooja Das; Ayushi Gupta; Vikas Kakkar; Arun Kumar; Varun Arya
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-06-17

8.  Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials.

Authors:  Jonathan A C Sterne; Janet Diaz; Jesús Villar; Srinivas Murthy; Arthur S Slutsky; Anders Perner; Peter Jüni; Derek C Angus; Djillali Annane; Luciano Cesar Pontes Azevedo; Bin Du; Pierre-Francois Dequin; Anthony C Gordon; Cameron Green; Julian P T Higgins; Peter Horby; Martin J Landray; Giuseppe Lapadula; Amelie Le Gouge; Marie Leclerc; Jelena Savović; Bruno Tomazini; Balasubramanian Venkatesh; Steve Webb; John C Marshall
Journal:  Trials       Date:  2020-08-24       Impact factor: 2.279

9.  Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome.

Authors:  Zesemayat K Mekonnen; Davin C Ashraf; Tyler Jankowski; Seanna R Grob; M Reza Vagefi; Robert C Kersten; Jeffry P Simko; Bryan J Winn
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Mar-Apr 01       Impact factor: 2.011

View more
  2 in total

1.  Rhino-orbito-cerebral mucormycosis in an acute lymphoblastic leukemia pediatric patient. Case report and review of literature.

Authors:  Cindy Carolina Abril Rincón; Carlos Ramiro Silva-Ramos; Joel Amuruz Arancibia; Ma Camila Prada-Avella; Amaranto Suárez
Journal:  Infez Med       Date:  2022-06-01

Review 2.  COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic.

Authors:  Pankaj Chandley; Priyanka Subba; Soma Rohatgi
Journal:  Vaccines (Basel)       Date:  2022-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.